MedTrace Logo

Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation

NCT01839721 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2013-05-17

No results posted yet for this study

Summary

In this double-blinded randomized clinical trial study, investigators assessed probiotic used to prevent or delay radiation induced grade moderate to severe diarrhea with patient treated for pelvic cancer.

Conditions

Interventions

DRUG

Bifilact®

placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day

OTHER

placebo

Sponsors & Collaborators

  • CHU de Quebec-Universite Laval

    lead OTHER

Principal Investigators

  • Dagnault Anne, PhD · CHU de Quebec

  • Josee Desjardins, B.Sc, RD · Chu de Quebec

  • Mimi Demers, B.Sc. RD · CHU de Québec

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-11-30
Completion
2010-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01839721 on ClinicalTrials.gov